Problemi u vezi sa lekovima kod bolesnika sa osteoporozom
Sažetak
Uvod/Cilj. Problemi zbog lekova posebno su česti kod bolesnika nezaraznim bolestima, kao što su osteoporoza, što je dovelo do suboptimalnog doziranja u lečenju. Cilj ove studije bio je da identifikuje probleme izazvane lekovima kod bolesnika sa osteoporozom. Metode. Ova prospektivna studija sprovedena je u januaru 2014 na bolesnicima obolelim od osteoporoze u tri zdravstvene ustanove u Beogradu, Srbija. Bolesnici uključeni u studiju bili su stariji od 50 godina i oni su popunjavali anonimne upitnike sa otvorenim pitanjima. Rezultati. Od 355 učesnika, 329 (92,7%) bile su osobe ženskog pola, a 26 (7,3%) muškog. Bolesnici koji su imali makar jedan prelom zbog osteoporoze (n = 208) statistički značajno manje su pristalice terapije, manje su se bavili sportom i redovnim fizičkim aktivnostima, a više su bili skloni ishrani sa neadekvatnim unosom kalcijuma i vitamina D, nego bolesnici bez preloma (n = 147). Zaključak. Efikasnost lečenja osteoporoze snižena je zbog nekoliko problema u vezi sa lekovima sa kojima se susreću kako lekari, tako i bolesnici. Međutim, na većinu problema u vezi sa lekovima moglo bi se u velikoj meri uticati odgovarajućim obrazovnim programima.
Reference
Kempen TG, van de Steeg-van GC, Hoogland P, Liu Y, Bouvy ML. Large scale implementation of clinical medication reviews in Dutch community pharmacies: drug-related problems and interventions. Int J Clin Pharm 2014; 36(3): 630−5.
Cancian M, Battaggia A, Celebrano M, Del Zotti F, Novelletto BF, Michieli R, et al. The care for chronic heart failure by general practitioners. Results from a clinical audit in Italy. Eur J Gen Pract 2013; 19(1): 3−10.
Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFP. Arch Osteoporos 2013; 8(1−2):136.
Lesić A, Jarebinski M, Pekmezović T, Bumbasirević M, Spasovski D, Atkinson HD. Epidemiology of hip fractures in Belgrade, Serbia Montenegro, 1990-2000. Arch Orthop Trauma Surg 2007; 127(3): 179−83.
Salari Sharif P, Abdollahi M, Larijani B. Current, new and future treatments of osteoporosis. Rheumatol Int 2011; 31(3): 289−300.
Machado-Alba J, Alzate-Carvajal V, Mondragón-Cardona A, Jiménez-Canizales CE. Low frequency of prophylaxis prescription for osteoporosis in patients receiving chronic treatment with corticosteroids in Colombia. Rev Peru Med Exp Salud Publica 2013; 30(1): 26−30. (Spanish)
Lai PS, Chua SS, Chan SP. Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates. J Clin Pharm Ther 2012; 37(5): 536−43.
Yu S, Chou C, Lai H, Chen Y, Chiu C, Kuo M, et al. Adherence to anti-osteoporotic regimens in a Southern Taiwanese population treated according to guidelines: a hospital-based study. Int J Rheum Dis 2012; 15(3): 297−305.
Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007; 82(12): 1493−501.
Leikola SN, Virolainen J, Tuomainen L, Tuominen RK, Airaksinen MS. Comprehensive medication reviews for elderly patients: Findings and recommendations to physicians. J Am Pharm Assoc 2012; 52(5): 630−3.
Cadarette SM, Carney G, Baek D, Gunraj N, Paterson JM, Dormuth CR. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. Osteoporos Int 2012; 23(4): 1475−80.
Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003; 5(12): 859−62.
La P, Chua SS, Chan SP. Medication adherence and other issues encountered by patients with osteoporosis. Malay J Pharmac Sci 2005; 3(2): 70.
Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S. Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. Osteoporos Int 2014; 25(6): 1807−12.
Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010; 21(11): 1943−51.
Mikyas Y, Agodoa I, Yurgin N. A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men. Appl Health Econ Health Policy 2014; 12(3): 267−77.
Cesarec G, Martinec S, Basić I, Jakopić D. Effect of exercises on quality of life in women with osteoporosis and osteopenia. Coll Antropol 2014; 38(1): 247−54.
Varacallo MA, Fox EJ. Osteoporosis and its complications. Med Clin North Am 2014; 98(4): 817−31.
Chahal J, Lee R, Luo J. Loading dose of physical activity is related to muscle strength and bone density in middle-aged women. Bone 2014; 67:41-45. doi: 10.1016/j.bone.2014.06.029
Nshimyumukiza L, Durand A, Gagnon M, Douville X, Morin S, Lindsay C, et al. An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res 2013; 28(2): 383−94.
Gunn CA, Weber JL, Kruger MC. Diet, weight, cytokines and bone health in postmenopausal women. J Nutr Health Aging 2014; 18(5): 479−86.
Millar H, Davison J. Nutrition education for osteoporosis prevention in men with prostate cancer initiating androgen deprivation therapy. Clin J Oncol Nurs 2012; 16(5): 497−503.